The randomized, blinded, placebo-controlled clinical trial is conducted on 5 healthy volunteers and 5 patients with type 1 diabetes.~All study subjects receive once a placebo and once 10 micrograms of lixisenatide.~The order of administration of study medication is decided on randomization. The placebo and lixisenatide are administered at least 2 days apart.~Blood samples are taken 30 minutes and immediately before study medication administration and 30, 60, 90, 120, and 150 minutes after study medication administration,.~The primary endpoint is the peak value of growth hormone measured during the 2,5 hours after study medication administration.
The current study has two aims:~to test the hypothesis that a single dose of lixisenatide can be used as a growth hormone stimulation test;~to test if the growth hormone-stimulating effect is mediated by changes in blood glucose.~The secondary objective of the study is to monitor the effect of lixisenatide on other pituitary hormones and physiological parameters (blood glucose, blood pressure, heart rate, nausea).